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ing the first recommendation in favour of the innovation, and then subsequent
entrants’ prices are reduced through procurement competition as well as their
lower likely required R&D investments. CONCLUSIONS: The study finds that HTA
decisions on medical devices can have a material impact on the market dynamics
(and so prices) following a recommendation, because of themanner inwhichmed-
ical devices are procured. The findings of HTAwill therefore vary depending on the
point in time when it is undertaken, as relative prices change substantially over
time. Re-reviewing cost-effectiveness, without any new clinical evidence, relative
to a technology that has had a ‘disinvestment recommendation’ would therefore
appear perverse, as it sets up a feedback loop that causes a perpetual downward
spiral in prices. The study raises a number of policy issues for consideration. These
include the interplay between different drivers of value in HTA and procurement,
and the implicit ‘genericisation’ of evidence through the procurement process.
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OBJECTIVES: The current global economic climate is putting increasing pressure
on governments and payers to cut health care cost but continue to fund and grant
reimbursement to innovative Medicines, Devices & Biotechnologies that demon-
strate benefit to patient’s quality of life. One fundingmodel that is attracting inter-
est is patient co-payment (co-pay). Patient co-paymodels are being used globally to
allow patient access to medicines and medical technologies. However in United
Kingdom and Europe these types of funding models are still being evaluated and
assessed. A survey was designed to uncover the attitudes of physicians and pa-
tients towards co-pay models as potential funding mechanism for gaining access
to new and innovative technologies.METHODS: The United Kingdomwas selected
to carry out research to gauge the opinions of physicians and patients towards
co-pay. A total of 150 specialist physicians involved in making budget decisions
were surveyed via an internet based questionnaire and in a second survey 558
patients were interviewed face to face to evaluate their attitudes towards co-pay
for new and novel technologies. The results from these two surveys were statisti-
cally analysed to reveal the attitudes of these two key groups toward patient co-pay
and draw some initial conclusions. RESULTS: The analysis and results from the
patient survey showed that 83% of patients would consider co-pay as way of gain-
ing access to new technologies that were not fully reimbursed by the UK public
healthcare system. The physician’s survey showed that 72% of the 150 of specialist
supported the co-pay concept in principle. CONCLUSIONS: This UK research con-
cluded that both physicians and patients would consider co-pay as a funding op-
tion to gain access to new technologies. Additional stakeholder research is antici-
pated to answer the implications surrounding equity and coverage and provide
multiple stakeholders with insights into novel funding mechanisms for new tech-
nologies.
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OBJECTIVES: Concerns have been raised regarding growth in advanced diagnostic
imaging use. This study evaluated national outpatient MRI/CT utilization rates
during 2000-2009 and factors associated with imaging utilization.METHODS: This
retrospective database analysis used data on all respondents in the nationally
representative U.S. Medical Expenditure Panel Survey (MEPS) during 2000-2009.
Visits involving advanced diagnostic imaging were identified based on self-re-
ported use of MRI or CT tests at emergency rooms, office-based medical providers,
and outpatient departments. The imaging utilization rate was defined as the num-
ber of outpatient visits with MRI/CT per 1,000 person-years. Results were weighted
to create nationally representative estimates at the person-year level for each year
and the pooled 10-year period. A multivariate logistic regression was estimated to
identify predictors of imaging use. RESULTS: A total of 319,246 person-years were
included in the analysis. MRI/CT utilization rates increased from 64.3 to 109.1 per
1,000 person years from 2000 to 2009, with older persons, females and Medicare
enrollees having higher rates of use. Growth in imaging slowed in recent years; the
average annual decline in the imaging growth rate was larger than that for all
outpatient services (4.7% vs. 0.9%). The percentage of respondentswithMRI/CT use
(6.7% during 2000-2009) also increased at a slower rate in later years and declined
during 2007-2009. The average number of MRI/CT visits among imaging users was
steady at about 1.5 visits during 2000-2009. Age, female gender, white race, HMO
participation, and all payer types (vs. uninsured) were significant predictors of
imaging use. Compared to 2005, years 2000-2003 were associated with a signifi-
cantly lower likelihood of imaging use , while years 2004-2009 were not signifi-
cantly associated, suggesting a slow-down in later years. CONCLUSIONS: Growth
in advanced imaging utilization appears to have slowed in recent years, a finding of
potential interest to policy-makers and payers.
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OBJECTIVES: The objective of this research was to examine how regulatory re-
quirements in the inpatient setting impact the uptake and subsequent market
presence of MDDs (medical devices and diagnostics).METHODS: Primary research
was conducted through 48 in-depth interviews ranging from 30 to 60 minutes in
length. Subjects selected represent key stakeholders from industry, insurance,
government, and health services across 9 major markets (EU 5, United States, Ja-
pan, Canada, and Australia). Interview questionnaires were designed to under-
stand the national opportunities, market access barriers, and cross-country mar-
ket dynamics. This was complemented by secondary desk research that included
literature reviews, government and other relevant agency websites, and IHS pro-
prietary Healthcare and Pharmaceutical services. RESULTS: The study found that
the uptake of innovative devices is affected by the reimbursement environment in
hospitals as these serve as the largest consumers ofMDDs.While hospitals operate
under either global budgets or activity-based funding (DRG system), both funding
mechanismspossess limitations to the uptake of new technologies acrossmarkets.
Under global budgets, MDDs compete against other technologies and procedures
for budget allocation whereas DRG systems use a flat reimbursement rate that acts
as a financial disincentive to use more expensive technologies. Interviewees also
highlighted additional levers that can affect MDD update, including infrequent
coding system revisions, infrequent tariff updates for payments, and the existence
of add-on funding mechanisms, which differ across markets. CONCLUSIONS:
Across the markets considered, the inpatient reimbursement framework tends to
make for fragmented and subpar uptake of innovative MDDs. Indeed, the hospital
funding systems and notably infrequent revision of DRG codes, tariff updates and
complex top-up payment systems, when they exist, hamper new technology up-
take in an industry where incremental innovation is rapid.
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OBJECTIVES: To conduct a review of cervical cancer screening HTAs to understand
how new technologies are evaluated. METHODS: The INAHTA website, CRD (Uni-
versity of York) and Avalere CER Intelligence databases, Google, and country
agency websites were searched for “cervical cancer screening” and “HTA” pub-
lished 2000–2011. Reports unrelated to a screening intervention or not fully avail-
able in English were excluded. Topics, technologies, clinical results, primary or
literature-based economic analysis, and incremental cost-effectiveness ratios (IC-
ERs) were abstracted and analyzed. RESULTS: Twenty-five cervical cancer HTA
reports were identified and 17 HTAs from 9 countries met inclusion criteria. Five
technology types were evaluated: 2 cytology tests (conventional cytology (CC), liq-
uid-based cytology (LBC)), 2 Human papillomavirus (HPV) molecular tests, and 1
computer-guided screening system. All 17 HTAs evaluated test sensitivity and
specificity as themeasures of clinical effectiveness. An ICER result was included in
11HTAswith 73% (8/11) of recommendations derived fromprimary economic anal-
ysis. All eight HTAs reporting primary economic analysis incorporated sensitivity
analyses to test various screening intervals. Six reports addressed cost-effective-
ness of LBC compared to CC. Of these, 66% (4/6) concluded that LBC can be a
cost-effective strategy compared to CC at specified intervals. HPV versus cytology
as a primary screening test was an increasingly common topic; comparing 2000-
2005 to 2006-2011, this topic’s inclusion increased 63% (from 43% (3/7) - 70% (7/10)).
One of three HTAs reporting an ICER for HPV primary screening concluded it is
a cost-effective strategy within the context of the screening program.
CONCLUSIONS: Over the last 12 years, seventeen HTAs on cervical cancer screen-
ing evaluated the role of cytology and molecular testing as a primary screening
intervention. Incremental cost-effectiveness (9/17), test sensitivity and specificity
(17/17) and the ability to extend screening intervals (8/17) were the most common
measures used in HTA to evaluate new screening technologies.
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OBJECTIVES: The purpose of this study is to better quantify how urine drug mon-
itoring (UDM) is used in clinical practice. While several published studies have
reported utilization of UDM in clinical practice, little is known about how often
patients are monitored, which patients are monitored, which substances are im-
portant to detect, and under what circumstances clinicians modify the frequency
of monitoring. METHODS: An online survey was developed based on qualitative
phone interviews with eight clinicians who use UDM as a routine component of
clinical practice. One thousand fourteen randomly selected clinicians known to
order urine toxicology screenings were invited by mail to respond to the online
survey assessing their clinical needs and preferences with regards to UDM. Ninety-
three responses were received before the online survey was closed. RESULTS: Of
the 93 respondents, 43% (n40) self-identified as painmanagement specialists and
another 42% (n39) as family/internal medicine practitioners. Seventy-six percent
of respondents (n72) require all new patients to have UDM performed when they
enter their clinic. The majority administer UDM to chronic opioid therapy patients
four times a year. Overall, the respondents showed broad support to test patients
consistently for themost common illicit drugs, themajority of opioids, and a hand-
ful of prescription medications associated with abuse. Ninety-one percent of re-
spondents stated that all of their patients are tested for the same substances,
regardless of abuse history. The most common reasons cited by clinicians for a
change in the frequency of monitoring are patient history of substance abuse and
aberrant behaviors. CONCLUSIONS: Despite a lack of agreement between guide-
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